Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Autorzy:
Mateos MV; Hospital Universitario de Salamanca, Salamanca, Spain. . Gavriatopoulou M; Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Facon T; CHU Lille Service Des Maladies du Sang, 59000, Lille, France. Auner HW; Imperial College London, London, UK. Leleu X; Department of Hematology, CHU La Miletrie and Inserm CIC 1402, Poitiers, France. Hájek R; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic. Dimopoulos MA; National and Kapodistrian University of Athens, Athens, Greece. Delimpasi S; General Hospital Evangelismos, Athens, Greece. Simonova M; Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine, Lviv, Ukraine. Špička I; Charles University and General Hospital, Prague, Czech Republic. Pour L; University Hospital Brno, Brno, Czech Republic. Kriachok I; National Cancer Institute, Kiev, Ukraine. Pylypenko H; Cherkassy Regional Oncological Center, Cherkassy, Ukraine. Doronin V; City Clinical Hospital #40, Moscow, Russian Federation. Usenko G; City Clinical Hospital No. 4 of Dnipro City Council, Dnipro, Ukraine. Benjamin R; Kings College Hospital NHS Foundation Trust, London, UK. Dolai TK; Nil Ratan Sircar Medical College and Hospital, Kolkata, India. Sinha DK; State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna, India. Venner CP; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada. Garg M; University Hospitals of Leicester NHS Trust, Leicester, UK. Stevens DA; Norton Cancer Institute, St. Matthews Campus, Louisville, KY, USA. Quach H; St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia. Jagannath S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Moreau P; Hotel-Dieu, University Hospital, Nantes, France. Levy M; Baylor University Medical Center, Dallas, TX, USA. BadrosAZ; Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, USA. Anderson LD Jr; Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA. Bahlis NJ; Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, USA. Cavo M; Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy. Chai Y; Karyopharm Therapeutics Inc, Newton, MA, USA. Jeha J; Karyopharm Therapeutics Inc, Newton, MA, USA. Arazy M; Karyopharm Therapeutics Inc, Newton, MA, USA. Shah J; Karyopharm Therapeutics Inc, Newton, MA, USA. Shacham S; Karyopharm Therapeutics Inc, Newton, MA, USA. Kauffman MG; Karyopharm Therapeutics Inc, Newton, MA, USA. Richardson PG; Dana Farber Cancer Institute, Boston, MA, USA. Grosicki S; Medical University of Silesia, Katowice, Poland.
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2021 Apr 13; Vol. 14 (1), pp. 59. Date of Electronic Publication: 2021 Apr 13.
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
Autorzy:
Farooq AV; University of Chicago Medical Center, Chicago, IL, USA. . Degli Esposti S; NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, UCL Institute of Ophthalmology, London, UK. Popat R; University College London Hospitals, NHS Foundation Trust, London, UK. Thulasi P; Emory Eye Center, Emory University, Atlanta, GA, USA. Lonial S; Emory University, Winship Cancer Institute, Atlanta, GA, USA. Nooka AK; Emory University, Winship Cancer Institute, Atlanta, GA, USA. Jakubowiak A; University of Chicago Medical Center, Chicago, IL, USA. Sborov D; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Zaugg BE; Moran Eye Center, University of Utah, Salt Lake City, UT, USA. BadrosAZ; University of Maryland School of Medicine, Baltimore, MD, USA. Jeng BH; Department of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore, MD, USA. Callander NS; University of Wisconsin, Carbone Cancer Center, Madison, WI, USA. Opalinska J; GlaxoSmithKline, Upper Providence, PA, USA. Baron J; GlaxoSmithKline, Upper Providence, PA, USA. Piontek T; GlaxoSmithKline, Upper Providence, PA, USA. Byrne J; GlaxoSmithKline, Upper Providence, PA, USA. Gupta I; GlaxoSmithKline, Upper Providence, PA, USA. Colby K; University of Chicago Medical Center, Chicago, IL, USA.
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
Autorzy:
Farooq AV; University of Chicago Medical Center, Chicago, IL, USA. . Degli Esposti S; NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, UCL Institute of Ophthalmology, London, UK. Popat R; University College London Hospitals, NHS Foundation Trust, London, UK. Thulasi P; Emory Eye Center, Emory University, Atlanta, GA, USA. Lonial S; Emory University, Winship Cancer Institute, Atlanta, GA, USA. Nooka AK; Emory University, Winship Cancer Institute, Atlanta, GA, USA. Jakubowiak A; University of Chicago Medical Center, Chicago, IL, USA. Sborov D; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Zaugg BE; Moran Eye Center, University of Utah, Salt Lake City, UT, USA. BadrosAZ; University of Maryland School of Medicine, Baltimore, MD, USA. Jeng BH; Department of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore, MD, USA. Callander NS; University of Wisconsin, Carbone Cancer Center, Madison, WI, USA. Opalinska J; GlaxoSmithKline, Upper Providence, PA, USA. Baron J; GlaxoSmithKline, Upper Providence, PA, USA. Piontek T; GlaxoSmithKline, Upper Providence, PA, USA. Byrne J; GlaxoSmithKline, Upper Providence, PA, USA. Gupta I; GlaxoSmithKline, Upper Providence, PA, USA. Colby K; University of Chicago Medical Center, Chicago, IL, USA.
Pokaż więcej
Źródło:
Ophthalmology and therapy [Ophthalmol Ther] 2020 Dec; Vol. 9 (4), pp. 889-911. Date of Electronic Publication: 2020 Jul 25.
Characteristics and outcomes of therapy-related myeloid neoplasms after treatment for multiple myeloma.
Autorzy:
Duong VH; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA. Holtzman NG; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA. Koka R; Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA. Singh ZN; Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA. Zou Y; Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA. Emadi A; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA. Rapoport AP; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA. Kocoglu MH; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA. Baer MR; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA. BadrosAZ; Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2019 Dec; Vol. 60 (14), pp. 3577-3580. Date of Electronic Publication: 2019 Jul 08.
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.
Autorzy:
Rapoport AP; The Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA. Stadtmauer EA; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Binder-Scholl GK; Adaptimmune Ltd, Oxford, UK. Goloubeva O; The Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.; Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD USA. Vogl DT; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Lacey SF; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. BadrosAZ; The Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA. Garfall A; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Weiss B; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Finklestein J; Department of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD USA. Kulikovskaya I; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Sinha SK; School of Mathematics and Statistics, Carleton University, Ottawa, Canada. Kronsberg S; The Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.; Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD USA. Gupta M; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Bond S; Cambridge Biomedical, Cambridge, Massachusetts, USA. Melchiori L; Adaptimmune Ltd, Oxford, UK. Brewer JE; Adaptimmune Ltd, Oxford, UK. Bennett AD; Adaptimmune Ltd, Oxford, UK. Gerry AB; Adaptimmune Ltd, Oxford, UK. Pumphrey NJ; Adaptimmune Ltd, Oxford, UK. Williams D; Adaptimmune Ltd, Oxford, UK. Tayton-Martin HK; Adaptimmune Ltd, Oxford, UK. Ribeiro L; Adaptimmune Ltd, Oxford, UK. Holdich T; Adaptimmune Ltd, Oxford, UK. Yanovich S; The Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA. Hardy N; The Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA. Yared J; The Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA. Kerr N; Department of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Philip S; The Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA. Westphal S; The Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA. Siegel DL; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Levine BL; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Jakobsen BK; Adaptimmune Ltd, Oxford, UK. Kalos M; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. June CH; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Pokaż więcej
Źródło:
Nature medicine [Nat Med] 2015 Aug; Vol. 21 (8), pp. 914-921. Date of Electronic Publication: 2015 Jul 20.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Autorzy:
Niesvizky R; a Medicine and Hematology/Oncology, Weill Cornell Medical College , New York , NY , USA. BadrosAZ; b Department of Medicine , University of Maryland Greenebaum Cancer Center , Baltimore , MD , USA. Costa LJ; c Department of Medicine and UAB-CCC , Bone Marrow Transplantation and Cell Therapy Program, University of Alabama , Birmingham , AL , USA. Ely SA; d Pathology and Laboratory Medicine, Weill Cornell Medical College , New York , NY , USA. Singhal SB; e Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine , Chicago , IL , USA. Stadtmauer EA; f Division of Hematology/Oncology, University of Pennsylvania Abramson Cancer Center , Philadelphia , PA , USA. Haideri NA; g Oncology/Hematology and Internal Medicine, Saint Luke's Health System , Kansas City , MO , USA. Yacoub A; h Hematology and Oncology, University of Kansas Medical Center , Kansas City , KS , USA. Hess G; i Department of Hematology , Oncology and Pneumology, University Medical School of the Johannes Gutenberg-University , Mainz , Germany. Lentzsch S; j Division of Hematology/Oncology, Columbia University Medical Center , New York , NY , USA. Spicka I; k 1st Department of Internal Medicine , Charles University , Praha , Czech Republic. Chanan-Khan AA; l Department of Hematology/Oncology , Mayo Clinic , Jacksonville , FL , USA. Raab MS; m Department of Internal Medicine V , University of Heidelberg, and German Cancer Research Center (DFKZ) , Heidelberg , Germany. Tarantolo S; n Methodist Hospital and Nebraska Cancer Specialists , Omaha , NE , USA. Vij R; o Section of BMT and Leukemia, Washington University School of Medicine , St. Louis , MO , USA. Zonder JA; p Oncology and Internal Medicine, Karmanos Cancer Institute/Wayne State University , Detroit , MI , USA. Huang X; d Pathology and Laboratory Medicine, Weill Cornell Medical College , New York , NY , USA. Jayabalan D; d Pathology and Laboratory Medicine, Weill Cornell Medical College , New York , NY , USA. Di Liberto M; d Pathology and Laboratory Medicine, Weill Cornell Medical College , New York , NY , USA. Huang X; q Pfizer Oncology , San Diego , CA , USA. Jiang Y; q Pfizer Oncology , San Diego , CA , USA. Kim ST; q Pfizer Oncology , San Diego , CA , USA. Randolph S; q Pfizer Oncology , San Diego , CA , USA. Chen-Kiang S; d Pathology and Laboratory Medicine, Weill Cornell Medical College , New York , NY , USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2015; Vol. 56 (12), pp. 3320-8. Date of Electronic Publication: 2015 May 15.
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.
Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
